L

, Juraj Payer2 and Manfred Herold3



(1)
National Institute for Rheumatic Diseases, Piestany, Slovakia

(2)
Fifth Department of Internal Medicine, Comenius University University Hospital, Bratislava, Slovakia

(3)
Department of Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria

 



Laboratory indicators of the bone turnover In the process of bone remodelling, the cross-link fragments of collagen enter the blood and then may be detected in the serum or urine.

At the present time, their assessment is utilised for:



  • Monitoring the effect of the treatment (a significant change can be seen in 3–6 months)


  • Prediction of bone loss, especially for the identification of the so-called fast losers, i.e. persons with increased bone turnover


  • Prediction of fracture risk independently of the bone mineral density scan

The individual markers differ by their specificity, sensitivity and severity of assessment, and their availability in the routine clinical practice. The significance of individual markers and their combination is still the subject clinical monitoring.

We subdivide the markers of osteoformation from the markers of osteoresorption.

Markers of osteoresorption



  • Cross-link compounds of collagen – deoxypyridinoline DPYR


  • C-terminal telopeptide fragment of type I collagen (CTX).


  • N-terminal telopeptide fragment of type I collagen (NTX)


  • C-telopeptide cross-link domain of type I collagen (ICTP)

Markers of osteoformation



  • Bone-specific isoenzyme of alkaline phosphatase (bALP)


  • Osteocalcin


  • Propeptides of type I procollagen (PICP, PINP)

Lactoferrin  Protein that contains iron, found in milk and in secondary granules of neutrophils in which it is involved in antimicrobial pathways by absorbing iron from the environment. Iron is crucial for the growth and reproduction of microorganisms.

LAK cells  These are lymphokine (mainly IL-2)-activated killer cells. NK cells are most frequently subject to activation, less frequently cytotoxic T lymphocytes. LAK cells are also able to lyse those target cells that cannot be lysed by less active NK cells. This has recently led to their use in the treatment of certain tumours.

Lambert–Eaton syndrome A complication of intrathoracic tumours, especially small cell lung cancer, though it may also be idiopathic, especially in younger women. Muscle weakness is the primary manifestation, but myalgias and paraesthesiae can occur.

Aetiology – decreased release of acetylcholine in the nerve terminals

EMG – has differential diagnostic value



  • ► Treatment

    Includes tumour excision or glucocorticoids/immunosuppression with limited success.

Laminin Glycoprotein of high molecular weight (MW 900 kDa) comprising three (alpha, beta and gamma) polypeptide chains. Fifteen different forms of laminin have been identified. Laminin belongs to adhesive molecules and is part of the intercellular matrix, where it is bound to collagen type IV, heparan and glycosaminoglycans participating in the formation of the basement membrane of many tissues, including vessels. It is involved in the adhesion and chemotaxis of neutrophils. Laminin is the morphogenic factor of epithelial cells and hepatocytes, and by binding to receptors on the surface of nerve cells, it enables mutual aggregation of these cells and the production of dendrites. It is produced by macrophages. The importance of laminins is illustrated by the fact that the dysfunctional structure of laminin-2 is the cause of some types of muscular dystrophy.

Large granular lymphocytes – see LGL (large granular lymphocytes)

Laser (light amplification by stimulated emission of radiation) therapy (LT) Utilisation of monochromatic (only one wavelength) polarised (undulation only on one plane) coherent (vibration in one phase) light for medical treatment. Only so-called low-level lasers with power of 40–200 mW are used in physiotherapy. Depending on the radiation technique, devices are divided into:

1.

Spot radiation

 

2.

Scanners

 

3.

Clusters; shower of lasers with several infrared diodes in one probe

 

Indications in rheumatology are painful damage of soft tissues such as tendinitis, bursitis, epicondylitis, myositis, periarthritis and osteoarthritic pain. Lasers can also be used for irradiation of acupuncture points referred to as ‘laser acupuncture’. In laser therapy, safety procedures and contraindications (eyes and thyroid gland irradiation in particular) must be respected.

Lazy leucocyte syndrome An older term for unidentified conditions associated with deficient chemotaxis of leucocytes leading to increased risk of pyogenic infections. Nowadays, specific causes of deficient chemotaxis have been identified, so the nomenclature has been modified, e.g. leucocyte adhesion deficiency (LAD) syndrome.

LcSSc – see Systemic sclerosis (SSc).

LE cells The history of antinuclear antibodies (ANA) began in 1948 when Hargreaves described the phenomenon of LE cells. An LE cell is a polymorphonuclear (PMN) leucocyte, which has phagocytosed the released nuclear material of another leucocyte. Antibodies against nucleosomes, which in vitro bind to a released nucleus, are responsible for the LE phenomenon. As a consequence of the binding, complement is activated, with opsonisation of nuclear material, and finally phagocytosis by a PMN leucocyte occurs. This results in the formation of a large lucid phagocytosed nucleus surrounded by small amounts of cytoplasm. The original nucleus of a phagocytosing leucocyte is compressed to the cell membrane. LE cells are typical for systemic lupus erythematosus, although they may occasionally be present in rheumatoid arthritis and systemic sclerosis. At present the detection of LE cells has been superseded and more sensitive techniques, such as immunofluorescent ANA detection, are used.

Lectins Proteins and glycoproteins which are able to specifically recognise and bind to different mono-, di- and trisaccharides. They activate the agglutination of erythrocytes and other cells and are polyclonal (non-specific) mitogens of lymphocytes (e.g. phytohaemagglutinin, concanavalin A). This property is enabled by the presence of glycocalyx, which is located on the surface of most of the cells and which contains different oligosaccharide chains. Lectins were originally isolated from plants but now are also known to be present in animals (so-called collectins in human and other mammals) and microorganisms.

Ledderhose’s disease A plantar fascial fibromatosis, also known as Morbus Ledderhose, and plantar fibromatosis, is a relatively rare non-malignant thickening of the plantar aponeurosis. It may occur at any age with the greatest prevalence at middle age and beyond. This disorder is more common in men than women, and it is often associated with Dupuytren’s disease.

Leflunomide A dihydroorotate dehydrogenase inhibitor which selectively blocks de novo synthesis of pyrimidines in rapidly proliferating activated lymphocytes. This suspends activated autoimmune lymphocytes in the G1/S phase of cell cycle, whilst not affecting other lymphocytes in G0 phase, as long as they are not needed in the immune response. Though primarily acting as an immunomodulating agent with anti-inflammatory activity, leflunomide does not have the property of a non-selective immunosuppressant. It inhibits IL-2 synthesis and the expression of adhesive molecules, decreasing the number of neutrophils that infiltrate the joint cavity.

Leflunomide belongs to the group of disease modifying antirheumatic drugs that have been registered for the treatment of rheumatoid arthritis (RA). Chemically, it is N-(4’-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide. It is administered orally with a bioavailability of about 80 %. An effective therapeutic level is reached approximately 6–10 h after administration. Leflunomide is metabolised in the liver and one of the active metabolites has very long biological half-time up to 14 days. A higher dose is often administered initially (100 mg a day during the first three days) to ensure more rapid achievement of equilibrium; otherwise, it can take up to 2 months if the maintenance dose (10–20 mg daily) is administered initially. Approximately 40 % of its metabolites are eliminated via the urine and 50 % via the stool.



  • ► Clinical efficacy

    The efficiency of leflunomide against placebo and other commonly used DMARDs in the treatment of RA has been tested. Clinical studies have proven comparable efficiency of leflunomide to methotrexate (MTX) and sulfasalazine (SSZ). It was shown that leflunomide improved inflammatory parameters such as the ACR 20 index in patients with RA, improves the quality of the patient’s life and delays radiological erosive progress in joints over 6 and 12 months of treatment. Leflunomide is also licensed for treatment of psoriatic arthritis.


  • ► Dosage

    Leflunomide can be administered at a dose of 100 mg per day for 3 days (though this is associated with a higher incidence of diarrhoea and so is now often avoided), followed by 10 mg or 20 mg over the long term. Its clinical effect is apparent at the end of the first month. Blood count and liver enzymes should be checked on a monthly basis. After discontinuation of leflunomide treatment due to severe toxicity, switching to another DMARD, e.g. MTX, or before conception, the patient must undergo a washout phase based on administration of 8 g of cholestyramine 3 times a day or administration of 50 g of activated charcoal 4 times a day for a period of 11 days.

    Only gold members can continue reading. Log In or Register to continue

    Stay updated, free articles. Join our Telegram channel

Oct 14, 2016 | Posted by in RHEUMATOLOGY | Comments Off on L

Full access? Get Clinical Tree

Get Clinical Tree app for offline access